Company* (Country; Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)

Accelrys Inc. (subsidiary of Pharmacopeia
Inc.; PCOP)

Personal Chemistry

Software licensing agreement
and technology alliance

Accelrys will license the use of and provide integration support for Accord for Oracle and Accord Chemistry Control (5/23)

Amarillo Biosciences Inc. (OTC BB:AMAR)

African Health Solutions LLC*

Licensing agreement providing
the rights to oral low-dose interferon alpha for the treatment of hepatitis B patients in Africa

African Health Solutions gains the rights in Africa (7/15)

Aviva Biosciences

Axon Instruments

Partnership in which Axon will make an equity investment in Aviva and provide ongoing support for the development program

Axon gains an exclusive technology license agreement, obtaining Aviva's intellectual property in design and fabrication of its planar patch clamp biochips; Aviva also will be the exclusive supplier of biochips for Axon's next-generation line of high-throughput ion channel measurement systems (6/11)

Genomics Inc.*


Three-year collaboration to develop an advanced software environment for interpreting systems biology data

The partnership also combines Beyond Genomics' systems biology informatics technology with Genstruct's Knowledge Assembly software (6/10)

Isogenica Ltd.*

Graseby Dynamics

Research collaboration to assess the utility of Isogenica's Covalent Display Technology

The technology will be assessed for rapidly identifying molecules that will bind with high affinity and specificity, in Graseby's detection equipment (7/10**)

Mining Corp.*


Technology collaboration to develop offerings that can help researchers analyze gene and protein expressions, discover relationships among the data to diseases and predict drug responses

In addition to joint sales and marketing efforts, IBM and Molecular Mining will explore research collaborations in areas such as visualization, pattern discovery and gene expression analysis (6/10)



LGC Ltd.* (UK)

Nonexclusive licensing agreement for a patent titled "Genetic Assay for Cytochrome P450 2D6"

Orchid obtained rights to market cytochrome P450 2D6 testing services in North America; financial details were not disclosed (6/7)

Prolinx Inc.*

Milian SA* (Switzerland)

Nonexclusive distribution agreement for Prolinx's RapXtract Superparamagnetic Separation Technology

Financial terms were not disclosed (6/18)

Proteome Systems Ltd.* (Australia)

Itochu Corp.* (Japan)

Joint venture agreement to form Proteome Systems Japan

The venture will provide proteomics research in the pharmaceutical, biotechnology, cosmetics, agriculture and research industries (6/3)

Rosetta Biosoftware
(unit of Rosetta Inpharmatics Inc., a subsidiary of Merck & Co. Inc.)


Three-year agreement to
integrate their flagship products

The deal provides connectivity between the Rosetta Resolver system and Spotfire DecisionSite's analytic application for genomics (5/28)

Symyx Technologies

Dow Chemical Co. (NYSE:

Multiyear extension to a research and development collaboration focusing on the discovery of catalysts to produce polyolefins

Dow will continue to fund Symyx's discovery efforts and will have exclusive rights to commercialize materials discovered within the collaboration; Symyx will receive royalties from any product sales (6/12)

Symyx Technologies

General Electric Co. (NYSE:GE)

Three-year patent licensing agreement that allows GE to practice certain Symyx combinatorial research methodologies covered under Symyx's issued patents

The license is limited by the number of experiments, and Symyx will receive annual payments during the term of the license (5/29)


# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.

ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board

No Comments